Parkinson's Disease Trial, Recruiting (NCT06582355)

Parkinson's Disease Trial, Recruiting NCT06582355 Sponsor: Maastricht University Medical Center Condition: Parkinson's Disease

Printed from Voxsanity (voxsanity.com.au) — NCT06582355 — Data sourced from ClinicalTrials.gov. Verify directly with the trial site before attending. Not medical advice.

Back to Parkinsons Disease

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

People who have been diagnosed with Parkinson's disease
People whose Parkinson's disease is at stage 1, 2, or 3 on a standard scale used to measure how far the condition has progressed (called the Hoehn and Yahr Scale)
People who are 18 years of age or older

Who may not be able to join:

People who have medical reasons that prevent them from having an MRI scan, such as having a heart pacemaker or certain metal implants in their body
People who have a history of a psychotic disorder, bipolar disorder, or psychotic depression
People who have used illegal drugs within the last four weeks
People whose alcohol consumption is currently excessive enough to interfere with their day-to-day life
People who score below 24 out of 30 on a standard memory and thinking assessment called the Montreal Cognitive Assessment (MoCA)
People who have any other condition that could interfere with the trial collecting clear and usable data (confirm with trial site)

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.

Last synced 20 July 2026

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.

Contact this trial

Principal Investigator: David EJ Linden, Prof., Maastricht University

Phone: +31 43 3881021

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Voxsanity

Clinical trials and treatments, explained plainly · voxsanity.com.au

Date:

To: My Doctor

Re: Clinical trial enquiry

I am writing to enquire about the following clinical trial which may be relevant to my care:

Trial: NCT06582355

Sponsor: Maastricht University Medical Center

Phase: Not Applicable

Status: Recruiting

Condition: Parkinson's Disease

Trial contact: +31 43 3881021

More information: https://clinicaltrials.gov/study/NCT06582355

Eligibility summary (AI generated)

Written by an AI model from ClinicalTrials.gov eligibility criteria and checked on a sample basis. Please confirm against the original criteria.

Who might be able to join this trial:

People who have been diagnosed with Parkinson's disease
People whose Parkinson's disease is at stage 1, 2, or 3 on a standard scale used to measure how far the condition has progressed (called the Hoehn and Yahr Scale)
People who are 18 years of age or older

Who may not be able to join:

People who have medical reasons that prevent them from having an MRI scan, such as having a heart pacemaker or certain metal implants in their body
People who have a history of a psychotic disorder, bipolar disorder, or psychotic depression
People who have used illegal drugs within the last four weeks
People whose alcohol consumption is currently excessive enough to interfere with their day-to-day life
People who score below 24 out of 30 on a standard memory and thinking assessment called the Montreal Cognitive Assessment (MoCA)
People who have any other condition that could interfere with the trial collecting clear and usable data (confirm with trial site)

Important: Always verify eligibility with the trial site directly before applying.

Access in Australia: A treatment being studied in a clinical trial is generally not yet listed on the PBS. Where a medicine is not approved or not available through a trial, the TGA Special Access Scheme may allow a doctor to access unapproved therapeutic goods for individual patients. See voxsanity.com.au/sas-navigator/ for a plain English explainer.

This information was sourced from ClinicalTrials.gov via Voxsanity (data last synced 20 July 2026). It is not medical advice. Please verify the trial's current status directly with the trial site before acting.

Trial details

Status

Recruiting

Phase

Not Applicable

Sponsor

Maastricht University Medical Center

Registry

ClinicalTrials.gov

Start date

10 February 2025

Est. completion

1 July 2026

Where this trial is recruiting

🇩🇪 Germany 🇳🇱 Netherlands

Primary endpoints

MDS-UPDRS (Unified Parkinson's Disease Rating Scale)

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 20 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov